TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24566733
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once daily for 2 and 4 weeks
Study: 24568177
Drug: Ziprasidone 40-160
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40-160 mg/day
Study: 24569099
Drug: Once-daily perphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily perphenazine dosing
Study: 24573552
Drug: Ultra low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultra low-dose IL-2 (100,000-200,000 IU/m(2) ×3 per week for 6 to 12 weeks)
Study: 24573552
Drug: Ultra low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultra low-dose IL-2
Study: 24574239
Drug: Ipilimumab, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab, an antagonist of CTLA-4
Study: 24576165
Drug: T-BiRD regimen
Normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-BiRD regimen (thalidomide 100 mg/day, lenalidomide 25 mg/day, dexamethasone 40 mg/day, clarithromycin 500 mg twice daily)
Study: 24576311
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment in repeated 6-week cycles)
Study: 24576794
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 42 days, LNG 150 mcg/EE 25 mcg for 21 days, LNG 150 mcg/EE 30 mcg for 21 days and EE 10 mcg for 7 days
Study: 24576794
Drug: Levonorgestrel/ethinyl estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel/ethinyl estradiol combined oral contraceptive
Study: 24581956
Drug: Flexible insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible insulin therapy (FIT) educational programme
Study: 24582505
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg orally twice a day
Study: 24582522
Drug: Live-donor uterus
Normalized name: Oryctolagus cuniculus uterus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-donor uterus transplantation (UTx) with low-dose induction immunosuppression
Study: 24583293
Drug: Hourly sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hourly sampling of cTnT
Study: 24583795
Drug: MK-2206 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 (200 mg weekly)
Study: 24587068
Drug: Psycho-educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psycho-educational intervention delivered by peer health workers (PHW); included a computer-assisted pre-test, educational video session, and a 6-week group program with weekly meetings.
Study: 24587318
Drug: Individual depressive
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual depressive symptoms (e.g., sad mood, concentration problems)
Study: 24589294
Drug: Etravirine 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 5.2 mg/kg (maximum dose 200 mg) twice a day (bid) plus optimized background regimen (OBR)
Study: 24589294
Drug: Etravirine 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 5.2 mg/kg bid plus OBR
Study: 24590637
Drug: Nivolumab (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (intravenous, every 2 weeks for up to 96 weeks)
Study: 24590653
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of TH, PHOX2B, or DCX mRNA in BM after induction therapy
Study: 24590653
Drug: Magnitude of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnitude of reduction in mRNA level between diagnosis and postinduction therapy in BM or PB
Study: 24590680
Drug: bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bovine lactoferrin (bLf) 100 mg twice a day
Study: 24590680
Drug: ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ferrous sulphate 520 mg once a day
Study: 24593248
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic treatment modification (n = 589; 28.9%)
Study: 24593248
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial antibiotic treatment modification
Study: 24593819
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g Osteoset® T with 4% tobramycin sulfate
Study: 24593819
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g Osteoset® T with 4% tobramycin sulfate
Study: 24593819
Drug: Osteoset® T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoset® T (10 g, 30 g, and 50 g)
Study: 24594870
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 48 weeks
Study: 24595069
Drug: Oramorph (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oramorph (5 mg every 6 hours)
Study: 24595454
Drug: GIP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIP regimen (gemcitabine 1000 mg/m² on days 1 and 5, ifosfamide 1200 mg/m²/day on days 1-5, cisplatin 20 mg/m²/day on days 1-5, granulocyte colony-stimulating factor 263 μg/day on days 7-15, repeated every 3 weeks for four cycles)
Study: 24595628
Drug: Insulin analog
Normalized name: insulin analog, glargine 300 UNT Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin analog therapy
Study: 24595628
Drug: End-of-study hypoglycemia
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-study hypoglycemia (insulin-naive group)
Study: 24598452
Drug: 5 million
Normalized name: colistin 1.5 million UNT Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 million EBV-CTLs/kg (1-3 doses)
Study: 24598881
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk zinc concentration and total milk volume measured using deuterium oxide dose-to-mother tracer technique.
Study: 24598881
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk zinc transfer measured using deuterium oxide dose-to-mother tracer technique.
Study: 24602182
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg IV every 3 weeks
Study: 24603117
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral treprostinil TID for 7 days
Study: 24603218
Drug: Gradient Gel
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradient Gel Electrophoresis (GGE)
Study: 24606093
Drug: Metformin extended
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin extended release 1500 mg/d for 12 weeks
Study: 24606096
Drug: No Growth
Normalized name: Mechano growth factor
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No Growth Hormone (GH) treatment (Control)
Study: 24606567
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral dose of trametinib
Study: 24606567
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg radiolabelled i.v. microdose of trametinib
Study: 24606768
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/day plus trastuzumab (loading, 4 mg/kg; then weekly 2 mg/kg or loading, 8 mg/kg; then 3-weekly 6 mg/kg)
Study: 24606768
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/day plus trastuzumab
Study: 24607242
Drug: Oral baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral baclofen (titrated from 2.5 mg 3 times a day to a maximum of 20 mg 4 times a day)
Study: 24607558
Drug: Median time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median time from initiation of chemotherapy to CDI
Study: 24610431
Drug: Medication (sertraline;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (sertraline; SRT)
Study: 24610431
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and medication (COMB)
Study: 24613995
Drug: Mexiletine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine administration to a carrier of the p.A997T-NaV1.5 mutation (1 individual)
Study: 24614108
Drug: Gemcitabine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine infusion during PDAC resection
Study: 24614178
Drug: Sequential radioembolization-sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radioembolization-sorafenib therapy (sorafenib 400 mg twice-daily initiated 14 days post-radioembolization with yttrium-90 resin microspheres).
Study: 24614178
Drug: Sequential radioembolization-sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radioembolization-sorafenib therapy (sorafenib 600 mg median dose/day for a median duration of 4.1 months).
Study: 24614178
Drug: Sequential radioembolization-sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radioembolization-sorafenib therapy (with 90Y-microspheres).
Study: 24614383
Drug: Rifapentine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (doses ranging from 450 to 1800 mg)
Study: 24614383
Drug: Rifapentine (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (once-daily dosing over 14 days)
Study: 24614383
Drug: Divided dosing
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dosing of rifapentine
Study: 24614947
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m²) plus Cisplatin (25 mg/m²) on days 1 and 8, every 3 weeks for up to 24 weeks
Study: 24615778
Drug: Idelalisib (50-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib (50-350 mg daily or twice daily)
Study: 24616310
Drug: Mogamulizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (1.0 mg/kg) administered intravenously once per week for 8 weeks
Study: 24617713
Drug: Vandetanib (tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (tyrosine kinase inhibitor)
Study: 24618504
Drug: Magnetically guided
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetically guided capsule gastroscopy
Study: 24618589
Drug: GC1008 (fresolimumab)
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC1008 (fresolimumab) at doses of 0.1, 0.3, 1, 3, 10, or 15 mg/kg administered intravenously on days 0, 28, 42, and 56, followed by Extended Treatment of 4 doses every 2 weeks for up to 2 additional courses.
Study: 24619017
Drug: Accelerated partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT) at a total dose of 36.9 Gy (nine fractions of 4.1 Gy b.i.d.)
Study: 24619321
Drug: Combined arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined arm (behavioral and medication management)
Study: 24619321
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management arm
Study: 24622344
Drug: Pedometer +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer + weekly prompts + SDT grounded texts
Study: 24622344
Drug: Pedometer +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer + weekly prompts
Study: 24622806
Drug: Milk diet
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk diet (semiskimmed milk-based diet, 1700 mg Ca/d)
Study: 24622806
Drug: Cheese diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheese diet (semihard cow-cheese-based diet, 1700 mg Ca/d)
Study: 24622806
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (nondairy diet, ~500 mg Ca/d)
Study: 24623282
Drug: Vismodegib, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib, 150 mg/d for a mean of 18.0 months (range, 11-24 months)
Study: 24623833
Drug: Maraviroc monotherapy
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc monotherapy for 10 days
Study: 24624090
Drug: Ephedrine (0.8-3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (0.8-3.3 mg/min)
Study: 24624090
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (0.02-0.07 mg/min)
Study: 24624979
Drug: Disease-modifying therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying therapy (DMT) compliance measured through pharmacy drug shipment records.
Study: 24625556
Drug: Dose-dense chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemoimmunotherapy with central nervous system prophylaxis
Study: 24625687
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 44 mcg subcutaneously (IFN β-1a SC) three times weekly
Study: 24626872
Drug: Aztreonam for
Normalized name: Aztreonam for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam for inhalation solution
Study: 29579617
Drug: Conventional cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cardiac resynchronization therapy (CRT)
Study: 24627529
Drug: NT-proBNP cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP cut-off value of 600 pg·mL(-1)
Study: 24627529
Drug: NT-proBNP ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP ≥ 600 pg·mL(-1)
Study: 24628963
Drug: XELBEVOCT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELBEVOCT regimen (octreotide LAR 20 mg monthly, metronomic capecitabine 2000 mg daily, intravenous bevacizumab 5 mg/kg every 2 weeks for 9 months)
Study: 24634374
Drug: Adoptive transfer
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes with DC vaccination (n = 10)
Study: 24634374
Drug: Adoptive transfer
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes without DC vaccination (n = 3)
Study: 24635447
Drug: Prolotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy with hypertonic dextrose and morrhuate sodium injections (15% dextrose and 5% morrhuate sodium) at peri-articular tendon and ligament insertions, and a single intra-articular injection of 6 mL 25% dextrose.
Study: 24635447
Drug: Prolotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy with hypertonic dextrose and morrhuate sodium injections.
Study: 24635447
Drug: Postprocedure opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprocedure opioid medication use.
Study: 24635447
Drug: Participant satisfaction
Normalized name: OCTINOXATE 0.28 g in 4 g TOPICAL LIPSTICK [SATIN SATISFACTION LIP COLOR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant satisfaction after prolotherapy injections.
Study: 24637635
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg) administered before tumor resection
Study: 24637635
Drug: Bevacizumab pharmacokinetics
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab pharmacokinetics
Study: 24637689
Drug: Danoprevir and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir and mericitabine combination treatment
Study: 24638072
Drug: Moderately intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately intensive chemotherapy for HIV-1 related lymphoma
Study: 24641955
Drug: Immunosuppressive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive agents (cyclophosphamide, glucocorticosteroids, mycophenolate mofetil)
Study: 24642016
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of autologous bone marrow-derived total nucleated cells (TNC)
Study: 24642016
Drug: MRI assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI assessment at 6 months post-therapy
Study: 24642140
Drug: Healthy Directions
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Directions 2 plus 2 brief telephone coaching calls (HD2+CC)
Study: 24642247
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin 1.8 mg/kg intravenously approximately every 3 weeks over 30 minutes
Study: 24643601
Drug: Fixed D-dimer
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed D-dimer cutoff of 500 µg/L
Study: 24646518
Drug: Oral 300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 300,000 units cholecalciferol administered at baseline and 8-weeks
Study: 24646562
Drug: Hepatic-arterial infusion
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev)
Study: 24646562
Drug: Hepatic-arterial infusion
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic-arterial infusion plus systemic chemotherapy without bevacizumab (Bev)
Study: 24647390
Drug: Homocysteine (μmol/L)
Normalized name: mecysteine
DrugBank: Homocysteine (DB04422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homocysteine (μmol/L)
Study: 24649361
Drug: Intrathecal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal clonidine 75 µg with bupivacaine (group C)
Study: 24649361
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 0.5 mL with bupivacaine (group F)
Study: 24649361
Drug: Intrathecal distilled
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal distilled water 0.5 mL with bupivacaine (group P)
Study: 24652992
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin 1.8 mg/kg administered every 3 weeks until progression or unacceptable toxicity
Study: 24653510
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/d) + Atorvastatin (10 mg/d)
Study: 24653510
Drug: Rosuvastatin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (2.5 mg/d)
Study: 24653520
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% solution (control group)
Study: 24653937
Drug: Levomilnacipran extended-release
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran extended-release 40-120mg/day
Study: 24655871
Drug: Sliding scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale insulin to lower blood glucose levels (n = 145)
Study: 24655871
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin (n = 98)
Study: 24661373
Drug: Patient controls
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controls (mRCC not receiving systemic treatment)
Study: 24661784
Drug: C1 esterase
Normalized name: C1 esterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor concentrate (C1-INH) at 20 IU/kg
Study: 24662454
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus cisplatin and vinorelbine (chemotherapy)
Study: 24664935
Drug: TNFα antagonist
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNFα antagonist therapy
Study: 24665992
Drug: Defibrillator with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrillator with cardiac resynchronization therapy (n = 132)
Study: 24667011
Drug: Sequential application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential application of four preventive measures
Study: 24668831
Drug: Cryocontact therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryocontact therapy
Study: 24668858
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg orally three times a week
Study: 24669960
Drug: IV rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV rt-PA treatment
Study: 24670165
Drug: Ceritinib (LDK378)
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib (LDK378) at doses of 400 mg or more per day
Study: 24670608
Drug: Temozolomide at
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide at 150 mg/m(2)/day on days 1-7 and days 15-21 during each 4-week cycle
Study: 24670710
Drug: Totally subcutaneous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Totally subcutaneous implantable defibrillator (S-ICD)
Study: 24671831
Drug: RP-1127 (glyburide
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP-1127 (glyburide for injection)